- Home
- KIDS vs XFOR Comparison
KIDS vs XFOR Comparison
Compare KIDS & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KIDS | XFOR |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.2M | 407.5M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | KIDS | XFOR |
|---|---|---|
| Price | $16.43 | $4.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $24.67 | $9.00 |
| AVG Volume (30 Days) | 146.6K | ★ 427.6K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $98,049,000.00 | N/A |
| Revenue This Year | $14.07 | N/A |
| Revenue Next Year | $11.85 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.95 | N/A |
| 52 Week Low | $14.91 | $0.17 |
| 52 Week High | $23.70 | $6.63 |
Technical Indicators
Market Signals| Indicator | KIDS | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 52.97 |
| Support Level | $15.70 | $3.41 |
| Resistance Level | $19.15 | $4.16 |
| Average True Range (ATR) | 0.68 | 0.29 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 79.21 | 52.47 |
Price Performance
Historical ComparisonAbout KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.